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1. Introduction 
Monotherapy is a basic principle in all branches of clinical medicine, including psychiatry. It 
is a scientific principle where we are making an attempt to clarify one single therapeutic 
step, its wanted and unwanted effects, in isolation. According to this principle we make sure 
to start with the least aggressive approach. However, in daily clinical practice polypharmacy 
might be considered when treating patients who have only a partial response to the first 
prescribed monotherapeutic trial. 
With the introduction of the antidepressive medication in the 1960s we had access to two 
different classes of antidepressants: the tricyclic antidepressants (TCAs) and the monoamine 
oxidase inhibitors (MAO-Is). Together these drugs cover serotonin, noradrenaline and 
dopamine effects in the brain, which we still consider important to stabilize in the acute 
therapy of major depression. On the other hand, both classes of drugs have many other 
actions which are often considered as side-effects. 
The new generation of antidepressants became available in the late 1980s and most of them 
are much more selective in their action than the first generation antidepressants. Therefore 
they have less severe side effects, but must often be combined to obtain the same 
antidepressive effectiveness as the first generation antidepressants.  
In the following text we will introduce the most patient-friendly approach to obtain a 
rational polypharmacy in the acute therapy of major depression. This is based not only on 
the traditional classification of drugs by receptor profile and expected mechanism of action 
in the brain, but also on clinical monitoring by use of valid rating scales for both the wanted 
and unwanted effects upon the mind. 
2. The disease-centre model of antidepressants 
The tricyclic antidepressants (TCAs) and the monoamine oxidase inhibitors (MAO-Is) are 
the first generation of effective antidepressants. These types of drugs showed that major 
depression could be treated like other medical conditions, by covering the acute short-term 
treatment of four to eight weeks followed by a medium-term treatment, and the 
continuation phase of four to eight months (the relapse-prevention phase).  
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It was from this evidence that a “disease-centred” model emerged, in which antidepressants 
were seen to help the brain of the depressed patient by restoring the neuropathological states.  
Over the fifty years since the TCAs and MAO-Is were first marketed, their biological 
mechanisms of action in the brain have been extensively studied. All the TCAs are both 
serotonin and noradrenaline reuptake inhibitors, but also act on many other mechanisms 
(e.g. histamine blockers). However, they have no action on dopamine. At the receptor level 
they all stimulate the serotonin 1A receptor and the most potent of them, amitriptyline,  is 
also a serotonin receptor 2A blocker. The MAO-Is, as they inhibit the enzyme monoamine 
oxidase, act on both serotonin and noradrenaline as well as on dopamine. The MAO-Is 
probably also act on other processes in the brain, e.g. vitamin B6. We do know, however, 
that the MAO-Is are not antihistamines. 
Taken together the TCAs and the MAO-Is can be considered to be non-selective or 
multidimensional drugs, comparable to a more or less rational polypharmacy at the receptor 
level. This is even when used as monotherapy in the acute therapy of major depression. 
The new generation of selective antidepressants (the selective serotonin reuptake inhibitors 
(SSRIs)), or the selective noradrenaline and serotonin reuptake inhibitors (SNRIs) have a 
selective mechanism of action, thus avoiding polypharmacy. However, the new generation 
antidepressants such as the SSRIs or SNRIs are less effective than the TCAs. Even within the 
TCAs, amitriptyline was found to be superior to imipramine both in the acute therapy of 
depressed patients and in the relapse-prevention phase . 
3. Using the Hamilton depression scale (HAM-D17) to direct polypharmacy 
When discussing the difference between the first generation and the second generation 
of antidepressants, Moncrieff and Cohen claimed that the Hamilton Depression Scale 
(HAM-D) contains many items that are not specific to depression, for example: “… three 
items on sleep, two on anxiety and one on agitation can score up to 18 points (a total 
score between 19 – 22 on the Hamilton Rating Scale for Depression indicates severe 
depression). On these items, any drug with sedative effects would be likely to 
outperform placebo…” 
However, with correct clinical use, the Hamilton Depression Scale covers the three clinical 
dimensions that have to be taken into account in the acute therapy of major depression in order 
to institute rational polypharmacy within the “disease-control” model of antidepressants. This 
correct clinical approach is obtained by use of the tripartite A,B,C HAM-D. 
The HAM-D17 is a multidimensional depression rating scale, implying that a total summed 
score of all the 17 items is not always a sufficient statistic, i.e. a profile score is needed.  
Recently Santen et al.  studied all placebo-controlled trials with the SSRI drug paroxetine 
and demonstrated that the most sensitive items in the HAM-D17 to discriminate between 
paroxetine and placebo were the six items in the HAM-D6. Actually, when using the HAM-
D17, the difference from baseline to endpoint between paroxetine 20 mg daily and placebo 
did not reach the level of P < 0.05, in contrast to HAM-D6 (P = 0.03) .  Furthermore, they 
found that with paroxetine 10 mg daily no difference to placebo was reached at the level of 
P < 0.05 for either HAM-D17 or HAM-D6, indicating a dose response pattern.  
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Pure depression Physiological arousal symptoms
(A)
(C)
(B)
1.         Depressed mood
2.         Guilt
7.         Activities and interests
8.         Psychomotor retardation
10. Anxiety, psychic
13.         Somatic symptoms - general
4.         Insomnia: initial
5.         Insomnia: middle
6.         Insomnia: late
9.         Psychomotor agitation
11. Anxiety, somatic
12. Gastrointestinal symptoms
14. Sexual disturbances
15. Hypochondriasis
17.         Weight loss
3.        Suicidal thoughts
16.        Insight
HAM-D6
Total score: 
HAM-D2
Total score: 
HAM-D9
Total score: 
Suicide risk behaviour
(A) (B)(C)
HAM-D17
Total score: (A+B+C)  
Fig. 1. ABC version of the depression scale (HAM-D) 
Fig. 1. Shows the three major components A, B, C in the HAM-D17 . Domain A in Figure 1 
covers the six pure depression symptoms in the HAM-D as used by experienced 
psychiatrists when measuring the severity of depressive states. Using item response theory 
models, the invariant item ordering of the HAM-D6 items was found by their prevalence at 
baseline and at the endpoint in clinical trials of antidepressants.  In the archetypical trial 
with the TCA amitriptyline in the setting of general practice, Paykel  showed that all items 
in the HAM-D6 discriminated between the TCA and placebo in both mild and moderate 
degrees of depression. Among the other HAM-D items only the sleep symptom showed 
discrimination, implying that amitriptyline is a sedative antidepressant. When comparing 
amitriptyline with the most sedative new generation antidepressant mirtazapine in placebo-
controlled trials, it was the HAM-D6 items that significantly differentiated between the 
active drugs and placebo, thereby prefiguring Moncrieff and Cohen’s critical remarks on the 
use of the HAM-D17 in measured outcome. 
Domain B in Figure 1 covers the physiological arousal symptoms, including the “sedative” 
HAM-D items selected by Moncrieff and Cohen. These nine symptoms (HAM-D9) in Figure 
1 were included by Hamilton in his HAM-D17 because they were found very common and 
distressing by the depressed patients themselves. As non-sedative antidepressants both the 
SSRIs and the SNRIs as well as the MAO-Is have to be combined with the antidepressants 
with antihistaminic action and/or serotonin receptor 2 blockers when the HAM-D9 profile is 
in operation in the depressed patients, i.e. when polypharmacy is rationally needed. In 
therapy-resistant depression it is often the physiological arousal symptoms that have been 
inadequately reduced. 
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Domain C in Figure 1 covers the two remaining items in HAM-D17 (suicidal thoughts and 
lack of insight). Due to the obvious clinical relevance of these items, their assessment is 
crucially important in the acute therapy of patients with major depression. It has even been 
questioned that SSRIs might induce suicidal thoughts over the first weeks of therapy. 
4. Patient related inventory of side effects (PRISE20) 
Table 1 shows the Patient Rated Inventory of Side Effects (PRISE), modified to monitor 
domain B selectively with 20 items (PRISE20).  
The first 17 items listed in Table 1 are derived from the original PRISE and the remaining 3 
items at the bottom in Table 1 are derived from the UKU (Udvalg for Kliniske 
Undersøgelser) subscale for antidepressants. The UKU scale is a clinician-rated scale 
whereas the PRISE is a patient-reported questionnaire. 
 
Have you had any of these side effects over the past two weeks? 
 No Yes, but tolerable Yes – Distressing 
1. Dry mouth   
2. Nausea   
3. Diarrhoea   
4. Constipation   
5. Dizziness   
6. Palpitations   
7. Sweating   
8. Headache   
9. Tremor   
10. Difficulty sleeping   
11. Sleeping too much   
12. Loss of sexual desire   
13. Trouble achieving orgasm   
14. Trouble with erections   
15. Anxiety   
16. Restlessness   
17. Decreased energy   
18. Increased appetite   
19. Increased weight   
20. Emotional indifference   
PRISE20 (Patient related Inventory of Side Effects) modified after Wisniewski et al.  
Table 1. 
This patient-administrated questionnaire was included in the STAR-D study (Bech et al. 
2012) so that the baseline score was used to evaluate before augmentation of citalopram with 
either bupropion or buspirone to ensure that the side effects to eight weeks treatment with 
citalopram were tolerable. In rational polypharmacy it is important to accept only tolerable 
side effects before any augmentation with other drugs.  
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In a post-hoc analysis of the STAR-D study, decreased energy was significantly reduced 
when citalopram was combined with bupropion (Bech et al. 2012). This symptom seems 
therefore to be an indication of lack of effect of citalopram rather than a side effect. 
In a similar way, many of the items in PRISE20 can be considered as physiological arousal 
symptoms of depression as covered by HAM-D9, e.g. difficulty sleeping, restlessness, 
anxiety, gastrointestinal symptoms or sexual symptoms. In the therapy-resistant depressed 
patients it is important to understand the nature of these symptoms, i.e. part of the 
depressive illness or drug-induced symptoms. 
5. Polypharmacy as a rational treatment with antidepressants monitored by 
the HAM-D17/PRISE20. 
Typically, antidepressants as monotherapy are now approved by the regulators (e.g. FDA) 
with reference to placebo-controlled clinical trials of patients with major depression. This 
makes comparative analyses between individual new generation antidepressants difficult. 
In some trials an active comparator (e.g. a TCA) has been included, which however, is 
compared with placebo using only the total HAM-D score as an outcome, not the profile 
score in accordance with the ABC version. 
In clinical practice, if a patient with major depression has failed to respond fully to the initial 
antidepressant, the treating physician can either augment by adding another drug to the 
initial antidepressant as part of a polypharmacy approach, or switch to another 
antidepressant with a quite different mechanism of action. 
The Sequenced Treatment Alternatives to Relieve Depression, the STAR*D study, is 
probably the most evidence-based trial to reflect the daily clinical practice. After failure to 
respond to monotherapy with the SSRI citalopram, patients went on to receive medication 
augmentation with bupropion-SR (sustained release) or buspirone in a controlled, double-
blind trial. 
Bupropion is a non-sedative second generation antidepressant with a selective reuptake 
inhibition of noradrenaline and dopamine (Table 2). It has a profile on the A, B and C HAM-
D17 similar to that of the SSRIs or SNRIs. This profile is also similar to the first generation of 
MAO-Is. Bupropion, like the MAO-Is, has an effect on dopamine  in contrast to the TCAs or 
SSRIs/SNRIs.. 
Within the antidepressants referred to as first generation, concomitant treatment with a TCA 
and an “irreversible” MAO-I (e.g. phenelzine or isocarboxazid) has rarely been used. If a 
patient with major depression fails to respond fully on the HAM-D6 with a TCA but still had 
some benefit on HAM-D9, it is then acceptable to add phenelzine or isocarboxazid. 
However, it is not considered acceptable to add a TCA in a patient with only partial 
response to a MAO-I due to the risk of cardiovascular problems (e.g. severely increased 
blood pressure leading to stroke). On the other hand, if the MAO-I has been stopped for 2 
weeks, then combination therapy with a TCA and the reinstated treatment with MAO-I is 
acceptable. The most frequently used TCA in this situation is amitriptyline. 
If initial therapy has been with an SSRI/SNRI, then the combination with a MAO-I, either an 
irreversible (e.g. isocarboxazid) or a reversible (e.g. moclobemide), might prove fatal. As 
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shown in the post hoc analysis of the STAR*D study data, there is no problem in a 
combination therapy with citalopram and bupropion SR. 
The TCAs were found to be superior to the MAO-Is. Because of their antihistamine action, 
the TCAs have a very strong and early onset effect on the arousal symptoms compared to 
citalopram, paroxetine or the MAO-I moclobemid. The most effective antidepressant is still 
amitriptyline. 
In Table 2 the second generation antidepressants mianserin and mirtazapine are also 
antihistaminergic, but with a less pronounced effect on HAM-D6.  However, mianserin differs 
from the TCAs by having no anticholinergic effect, which is important when treating elderly 
depressed patients due to the side effects of anticholinergics on cognitive functioning. 
However, as shown in Table 2, all antihistamines have weight gain as a serious side effect. 
 
-  No clear effect 
+ Clear effect, mild to moderate 
++ Clear effect, moderate to marked 
+++ Clear effect, marked to excellent/severe
HAM-D Side effects 
A 
Pure 
depression 
symptoms 
B 
Arousal 
symptoms 
Weight gain 
MONOTHERAPY    
First generation 
antidepressants 
TCAs (amitriptyline) +++ ++ ++ 
MAO-Is (isocarboxazid) + - - 
Second generation 
antidepressants 
Specific  
reuptake 
inhibitors 
SSRIs 
(citalopram/sertraline) + - - 
SNRIs 
(venlafaxine/duloxetine
) 
++ - - 
DNRI (bupropion) + - - 
NRI (reboxetine) + - - 
Second generation 
antidepressants 
Mianserin + ++ ++ 
Mirtazapine + ++ ++ 
Other Agomelatine + + - 
CONCOMITANT THERAPY    
Specific  
SSRI plus NRI ++ - - 
SSRI plus DNRI ++ - - 
SNRI plus DNRI plus 
agomelatine ++ + - 
Non-specific 
Mianserin/mirtazapine 
plus SSRI/SNRI +++ ++ ++ 
Mianserin/mirtazapine 
plus MAO-I ++ ++ ++ 
Monotherapy 
Mood stabilizers 
Lithium + - - 
Olanzapine + ++ ++ 
Concomitant      
therapy 
Olanzapine plus SSRI + + ++ ++ 
Lithium plus SSRI + + - - 
Rational polypharmacy of antidepressants in the acute therapy of major depression with reference to 
ABC HAM-D17. Concerning the optimal dose of the included drugs, see Papakostas et al.  
Table 2. 
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Concomitant therapy with mianserin and the MAO-I isocarboxazid has been found safe, but 
with weight gain as a problem. Concomitant therapy with mianserin and the SSRI fluoxetine 
has been evaluated in placebo-controlled trials by Dam et al. In this pilot study 13 patients 
received fluoxetine plus mianserin, while 17 patients received fluoxetine plus placebo. On 
the HAM-D17 the distance from baseline to endpoint (six weeks) was greatest for fluoxetine 
plus mianserin. However, even in this study approximately 30% had increased weight gain 
on the combination of mianserine plus fluoxetine whereas no weight gain was seen in the 
fluoxetine plus placebo treated group. A re-analysis of the data set has shown that it is on 
the arousal symptoms (HAM-D9, domain B, Figure 2) that the effect of the combination 
therapy is greatest. In a comprehensive study Blier et al.  have investigated the effect of 
monotherapy with fluoxetine compared to the combination of mirtazapine with fluoxetine 
or of mirtazapine with venlafaxine or of mirtazapine with bupropion. The results showed 
that the rate of remitters (HAM-D17 ≤ 7) increased from 25% with monotherapy to 
approximately 50% with any of the three mirtazapine combinations. However, in all these 
combination therapies weight gain was significantly increased compared to monotherapy 
with fluoxetine. Otherwise the combination therapy was safe. 
 
 
 
 
 
 
A   HAM-D6 (depression)  
0.35
P
57.5%
12.0 (1.4)
Flu + Pla
56.3%% 
improvement
at endpoint
12.6 (2.2)Baseline
Flu + Mian
B   HAM-D9 (arousal)
C   HAM-D2 (suicide)
A B
C
0.08
P
53.8%
9.1 (3.7)
Flu + Pla
71.4%% 
improvement
at endpoint
11.2 (3.1)Baseline
Flu + Mian
0.23
P
76.9%
1.3 (1.3)
Flu + Pla
80.0%% 
improvement
at endpoint
2.0 (1.5)Baseline
Flu + Mian
 
 
 
 
 
 
 
Fig. 2. A re-analysis of the dataset in Dam et al. 1998 
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In Table 2 the new generation antidepressant agomelatine is included. So far this drug has 
not been approved by the FDA as an antidepressant, but it is on the market in many 
European countries. Agomelatine acts by blocking the serotonin receptor 2, as mianserin or 
mirtazapine, but in contrast to these two drugs, without any antihistaminergic effects and 
therefore without weight gain as a side effect. However, agomelatine also has a selective 
effect on melatonin, thereby acting on sleep within the arousal symptoms in the HAM-D9. 
We still have no firm data from controlled clinical trials on concomitant therapy with 
agomelatine and SSRIs/SNRIs, but clinical experience is indicated in Table 2. An anecdotal 
report of a safe combination of agomelatine and MAO-I is now available.  
Table 2 also includes the mood-stabilizing drug lithium. The major indication for lithium 
therapy is its prophylactic effect in both bipolar and unipolar affective disorder. However, 
in the acute therapy of major depression, in a low dose (serum concentration of 0.4 – 0.5 
mmol/l), lithium is one of the most effective drugs, helping to obtain a response in therapy-
resistant depression. Its anti-suicidal effect is especially well-documented. The use of 
lithium in the acute therapy of major depression is referred to as augmentation, i.e. a non-
concomitant initial use, in which the decision to start lithium treatment follows an initial 
treatment trial with one antidepressant resulting in only partial response.  
Whereas concomitant therapy of lithium and an antidepressant seems most obvious in 
bipolar depression or depressed patients with hidden bipolarity , a concomitant therapy of 
olanzapine and an antidepressant (fluoxetine) has been shown to be effective not only in 
bipolar depression , but also in major depression . In the latter study, the HAM-D24 version 
was actually used, in this version specific items for hopelessness, helplessness and 
worthlessness have been included to strengthen domain A (Figure 1). 
The term ‘atypical antidepressants’ refers to the use of MAO-Is (especially phenelzine) in the 
treatment of atypical major depression – i.e. patients with pure depression symptoms (A in 
Figure 1) but with inverse physiological symptoms (hypersomnia and increased appetite). 
As a non-antihistaminergic drug, agomelantine might be used in combination with MAO-Is 
in the treatment of atypical depression. 
6. Polypharmacy: Pharmacokinetic considerations 
According to pharmacokinetic studies the TCAs are mainly metabolized by CYP 450 
enzyme system with the 2D6 substrate. Both agomelatine and mirtazapine are metabolized 
by the 1A2 substrate and therefore have no problems with CYP2D6 genetic polymorphisms. 
Among SSRIs we have listed citalopram and sertraline in brackets in Table 2 because these 
two antidepressants have the most acceptable pharmacokinetic profile. Among the SNRIs 
we have included both duloxetine and venlafaxine although desvenlafaxine might turn out 
to have the fewest drug-drug interactions in this class of antidepressants. Reboxetine and 
bupropion are metabolized through CTP3A4 but this seems only to be a problem when 
combined with the SSRI fluvoxamine. It is, however, recommended to consult specific 
reviews on pharmacokinetics when starting rational polypharmacy. In this review we have 
considered practical experience to be a valid guide. Thus, no problems with mirtazapine 
were found in the Blier et al. study. Mianserine was found to be safe both when combined 
with MAO-Is and with SSRIs (fluoxetine or citalopram). A combination of olanzapine and 
fluoxetine is also acceptable.  
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7. Conclusion 
The most selective second generation antidepressants have not proved in monotherapy to be 
more effective on the core symptoms of depression than the first generation TCAs or MAO-
Is. It is by their safety profiles, either in overdose or in terms of long term side effects, that 
the second generation antidepressants have outperformed the first generation. 
If we accept that amitriptyline is the most effective antidepressant ever marketed, we need 
to use rational polypharmacy with the second generation antidepressants in the acute 
therapy of major depression in order to obtain effectiveness similar to that of amitriptyline, 
but without problematic side effects such as anticholinergic actions. A combination of 
mianserine/mirtazapine and SSRI/SNRI (Table 2) is the most rational polypharmacy when 
compared to amitriptyline. On the other hand, weight gain as a serious side effect is also 
prevalent here.  
If a sedative effect on the HAM-D subscale of arousal symptoms (HAM-D9) is needed, 
agomelatine might be used in combination with the specific reuptake inhibitors (Table 2). 
Reboxetine, for example, is a very weak antidepressant but when combined with an SSRI 
there is anecdotal evidence that patients respond much more favourably than on the SSRI in 
monotherapy.  
The A,B,C HAM-D combined with PRISE20 should be used whenever rational 
polypharmacy is employed. 
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